$ACHV
ACHIEVE LIFE SCIENCES, INC.

2018 Q1 Form 10-Q Financial Statement

#000156459018012461 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.810M $2.530M
YoY Change -28.46% 10.0%
% of Gross Profit
Research & Development $1.201M $61.00K
YoY Change 1868.85% -6.15%
% of Gross Profit
Depreciation & Amortization $90.00K $93.00K
YoY Change -3.23% 66.07%
% of Gross Profit
Operating Expenses $1.201M $61.00K
YoY Change 1868.85% -99.17%
Operating Profit
YoY Change
Interest Expense $10.00K $30.00K
YoY Change -66.67% -40.0%
% of Operating Profit
Other Income/Expense, Net -$8.000K -$8.000K
YoY Change 0.0% 33.33%
Pretax Income -$3.022M -$329.0K
YoY Change 818.54% -91.13%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.022M -$205.0K
YoY Change 1374.15% -15.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$50.33M -$327.0M
COMMON SHARES
Basic Shares Outstanding 30.09M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.200M $784.0K
YoY Change 435.71% -98.3%
Cash & Equivalents $4.437M $24.00K
Short-Term Investments $760.0K
Other Short-Term Assets $600.0K $800.0K
YoY Change -25.0% 243.35%
Inventory
Prepaid Expenses $352.0K $765.0K
Receivables $7.000K $237.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.746M $17.45M
YoY Change -72.81% -63.63%
LONG-TERM ASSETS
Property, Plant & Equipment $18.00K $166.0K
YoY Change -89.16% -69.6%
Goodwill $1.034M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $135.0K $13.00K
YoY Change 938.46% -65.79%
Total Long-Term Assets $3.754M $451.0K
YoY Change 732.37% -47.31%
TOTAL ASSETS
Total Short-Term Assets $4.746M $17.45M
Total Long-Term Assets $3.754M $451.0K
Total Assets $8.500M $17.90M
YoY Change -52.52% -63.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $359.0K
YoY Change 11.42% -39.36%
Accrued Expenses $1.900M $1.400M
YoY Change 35.71% -86.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change 0.0%
Total Short-Term Liabilities $2.300M $1.980M
YoY Change 16.16% -86.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.300M $1.980M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.318M $2.012M
YoY Change 15.21% -86.22%
SHAREHOLDERS EQUITY
Retained Earnings -$15.72M -$200.2M
YoY Change -92.15%
Common Stock $21.85M $213.5M
YoY Change -89.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.142M $15.89M
YoY Change
Total Liabilities & Shareholders Equity $8.460M $17.90M
YoY Change -52.75% -63.31%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$3.022M -$205.0K
YoY Change 1374.15% -15.29%
Depreciation, Depletion And Amortization $90.00K $93.00K
YoY Change -3.23% 66.07%
Cash From Operating Activities -$2.233M -$9.000M
YoY Change -75.19% -0.99%
INVESTING ACTIVITIES
Capital Expenditures $1.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.00K $9.470M
YoY Change -99.89% -250.08%
Cash From Investing Activities $10.00K $9.470M
YoY Change -99.89% -250.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.105M -20.00K
YoY Change -5625.0%
NET CHANGE
Cash From Operating Activities -2.233M -9.000M
Cash From Investing Activities 10.00K 9.470M
Cash From Financing Activities 1.105M -20.00K
Net Change In Cash -1.119M 9.000K
YoY Change -12533.33% -100.06%
FREE CASH FLOW
Cash From Operating Activities -$2.233M -$9.000M
Capital Expenditures $1.000K
Free Cash Flow -$9.001M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3022000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-205000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.66
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12756752
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-205000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
222000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3022000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-329000
CY2017Q1 achv Recovery Of Deferred Income Taxes
RecoveryOfDeferredIncomeTaxes
-124000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3022000
CY2018Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2477000
CY2018Q1 us-gaap Liabilities
Liabilities
2318000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
13000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21840000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15716000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
6142000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8460000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2532000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
4746000
CY2017Q4 us-gaap Goodwill
Goodwill
1034000
CY2017Q4 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
877000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
7879000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
20556000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12694000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9892000
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
222000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7000
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
352000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000
CY2018Q1 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
774000
CY2017Q4 us-gaap Liabilities
Liabilities
2013000
CY2018Q1 us-gaap Goodwill
Goodwill
1034000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12747932
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1201000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11956752
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11947932
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12431488
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21230
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
86000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
56000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
181000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-217000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
207000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
149000
CY2018Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
94000
CY2017Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
113000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-103000
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
134000
CY2018Q1 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
27000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2233000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11000
CY2017Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
20000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1105000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1105000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20000
CY2018Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1119000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5556000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4437000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24000
CY2018Q1 achv Working Capital Balance
WorkingCapitalBalance
2200000
CY2017 achv Contingent Value Rights Liability Recovery
ContingentValueRightsLiabilityRecovery
200000
CY2017Q3 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
8600000
CY2017Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P6Y
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2017Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
167000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
223000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
223000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
223000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1418000
CY2018Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
0
CY2018Q1 us-gaap Cash
Cash
1133000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
272000
CY2018Q1 achv Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
CY2018Q1 achv Maximum Maturity Period Of Short Term Investments
MaximumMaturityPeriodOfShortTermInvestments
P1Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1115647
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3241
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1112406
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.99
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.89
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.00
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2000000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2018Q1 achv Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2017Q1 achv Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2018Q1 us-gaap Contractual Obligation
ContractualObligation
470000
CY2018Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
189000
CY2018Q1 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
281000
CY2018Q1 achv Expiration Of Operating Lease Agreement
ExpirationOfOperatingLeaseAgreement
2018-09
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
0
CY2018Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2018Q1 achv Indemnification Expense
IndemnificationExpense
0
CY2017Q3 achv Number Of Terminated Senior Executives
NumberOfTerminatedSeniorExecutives
1

Files In Submission

Name View Source Status
0001564590-18-012461-index-headers.html Edgar Link pending
0001564590-18-012461-index.html Edgar Link pending
0001564590-18-012461.txt Edgar Link pending
0001564590-18-012461-xbrl.zip Edgar Link pending
achv-10q_20180331.htm Edgar Link pending
achv-20180331.xml Edgar Link completed
achv-20180331.xsd Edgar Link pending
achv-20180331_cal.xml Edgar Link unprocessable
achv-20180331_def.xml Edgar Link unprocessable
achv-20180331_lab.xml Edgar Link unprocessable
achv-20180331_pre.xml Edgar Link unprocessable
achv-ex101_358.htm Edgar Link pending
achv-ex311_8.htm Edgar Link pending
achv-ex312_7.htm Edgar Link pending
achv-ex321_6.htm Edgar Link pending
achv-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending